Generic Drugs – Talk Bio

Teva Launches First Generic GLP-1 Weight-Loss Drug in the US

1 week ago talkbio0Tagged Approved, Generic Drugs, Glucagon-Like Peptide 1, liraglutide, Obesity, Saxenda, Teva, United States, United States Food and Drug Administration, Weight Loss

Teva; GLP-1; generic; weight loss; liraglutide; FDA approval; Saxenda; obesity treatment; United States

Indivior Initiates Cost-Cutting Plan with Job Cuts and Real-Estate Review

2 weeks ago talkbio0Tagged Advice, competition, cost-cutting, Generic Drugs, Indivior, Opvee divestiture, profit guidance, real-estate, restructuring, Sales - occupational activity

Indivior; job cuts; real-estate; cost-cutting; restructuring; sales guidance; profit guidance; Opvee divestiture; competition; generic drugs

Trump Locks in 15% Pharmaceutical Tariff Rate for EU, Generic Drugs Exempted

3 weeks ago talkbio0Tagged 15%, brand-name drugs, EU, Evaluation, Generic Drugs, Sectioning technique, tariff, tariff exemption, TNFRSF19 gene, transatlantic trade, Trump administration

15% tariff; pharmaceuticals; EU; Trump administration; generic drugs; trade deal; tariff exemption; brand-name drugs; transatlantic trade; Section 232 investigation

FDA Reinstates Generic Drug Policy Group After April Firings

3 months ago talkbio0Tagged Administrative action, Departure - action, development aspects, drug price, Generic Drugs, layoffs, Office, Policy, reinstatement, Transection (procedure), United States Food and Drug Administration

FDA; generic drugs; policy office; Division of Policy Development; reinstatement; layoffs; drug prices; administrative leave

Trump Tariffs Poised to Hit Drug Tool and Packaging Manufacturers: Industry Faces Rising Costs and Supply Chain Challenges

5 months ago talkbio0Tagged alpha 1-antitrypsin, Biopharma trade war, Drug Industry, Drug packaging industry, Generic Drugs, Impact food supplement, lobbying, Manufacturing, Market, onshoring, Pharmaceutical Supply Chain, pharmaceutical tariffs, Supply chain disruption, Trump tariffs, U.S., United States

Trump tariffs , Drug packaging industry , Pharmaceutical supply chain , API manufacturing costs , Biopharma trade war , U.S. manufacturing onshoring , Generic drugs market impact , Pharmaceutical tariffs , Supply chain disruption , Pharmaceutical industry lobbying

Novartis Sues FDA Over Approval of Entresto Generic After Petition Rejection

1 year ago talkbio0Tagged Entresto, exclusivity, Generic Drugs, Heart failure, Legal patent, Novartis, United States Food and Drug Administration

Novartis, FDA, Entresto, generic drug, lawsuit, patent exclusivity, heart failure medication